Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 October 2007Website:
http://lixte.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 04 Oct 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
LIXT Latest News
Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc.
-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company-
-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26 th Annual Global Investment Conference-
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing
PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO).
What type of business is Lixte Biotechnology Holdings?
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
What sector is Lixte Biotechnology Holdings in?
Lixte Biotechnology Holdings is in the Healthcare sector
What industry is Lixte Biotechnology Holdings in?
Lixte Biotechnology Holdings is in the Biotechnology industry
What country is Lixte Biotechnology Holdings from?
Lixte Biotechnology Holdings is headquartered in United States
When did Lixte Biotechnology Holdings go public?
Lixte Biotechnology Holdings initial public offering (IPO) was on 25 October 2007
What is Lixte Biotechnology Holdings website?
https://lixte.com
Is Lixte Biotechnology Holdings in the S&P 500?
No, Lixte Biotechnology Holdings is not included in the S&P 500 index
Is Lixte Biotechnology Holdings in the NASDAQ 100?
No, Lixte Biotechnology Holdings is not included in the NASDAQ 100 index
Is Lixte Biotechnology Holdings in the Dow Jones?
No, Lixte Biotechnology Holdings is not included in the Dow Jones index
When was Lixte Biotechnology Holdings the previous earnings report?
No data
When does Lixte Biotechnology Holdings earnings report?
The next expected earnings date for Lixte Biotechnology Holdings is 08 November 2024